An exploratory study suggests fujiKale may offer cardiovascular health benefits.
Although the American obsession with eating kale at restaurants may be on the decline, there are still reasons to get excited about the leafy superfood. Q’SAI USA (Torrance, CA) recently announced the results of a new exploratory study on its organic powdered kale ingredient, fujiKale, that suggest it may be effective at lowering blood pressure, blood glucose, and cholesterol.
Researchers at Kyushu University Graduate School of Medical Sciences (Fukuoka, Japan) studied 80 male and female participants aged 30-74 over the course of 12 weeks, tracking their blood pressure, blood glucose, and lipid metabolism. For the first four weeks, participants did not ingest the kale powder and were evaluated weekly for the aforementioned cardiovascular markers. For the final eight weeks, participants ingested 14g of fujiKale per day, typically by mixing the powder into water.
By the study’s conclusion, all of the cardiovascular markers showed improvement. Average systolic blood pressure rose slightly over the first four weeks prior to ingestion from 133 to 137.9, but by the end of the 12 weeks it had dropped to a group average of 129.2. Similarly, average diastolic blood pressure went from 86.1 at the beginning of the trial to 88.3 at the end of the 4-week pre-kale period, but dropped to 82.5 by the end of the study.
The group average for fasting blood glucose also dropped from 96.9 mg/dL before the kale ingestion period to 95.1 mg/dL at the study’s conclusion. LDL cholesterol decreased from an average 115.0 mg/dL at the start of the ingestion period to 109.6 mg/dL at the end of the study.
Results of the study, titled “An exploratory study of the efficacy of Q’SAI kale powder (fujiKale) on lifestyle diseases,” were announced at the 37th Annual Scientific Meeting of the Japanese Society of Hypertension.
“We have confirmed that Q’SAI kale powder (fujiKale) is effective in improving blood pressure, blood glucose, and lipid metabolism in study subjects,” said Tomomi Ide, who conducted the study and is an instructor at the Deparment of Cardiovascular Medicine at Kyushu University Graduate School of Medical Sciences.
The study comes on the heels of the U.S. release of fujiKale in January and the recent formation of Q’SAI USA as a U.S. subsidiary of the Japanase Q’SAI Co. (Fukuoka, Japan). The company says fujiKale has been sold in Japan for more than 30 years. One 5g scoop of fujiKale is equivalent to a 70g cup of chopped kale, according to a press release.
“It’s no secret that most Americans don’t eat enough vegetables, and many have yet to discover the nutritious value of kale,” said Murray Brannen, CEO, Q’SAI USA. “Fresh kale can be expensive and you have to clean it, cut it, and prepare it, which are obstacles in many households. But with fujiKale, it’s easy to add a vitamin-packed scoop to a variety of recipes, smoothies, or beverages.”
Study details are courtesy of Murray Brannen, CEO, Q’SAI USA.
Michael Crane
Associate Editor
Nutritional Outlook magazine
michael.crane@ubm.com
Photo © iStockphoto.com/tpzijl
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.
Recent review makes the case for testing omega-3 fatty acid levels in humans
May 23rd 2024The article commissioned by The Global Organization for EPA and DHA Omega-3s (GOED) reviewed the state of omega-3 fatty acid testing, highlighting the value of testing and the commercially available options for diagnostic testing.
Epax launches concentrated oil that combines omegas 3, 9, and 11
May 10th 2024The blend of long-chain polyunsaturated fatty acids and long-chain monounsaturated fatty acids combines the heart and brain health benefits of omegas-3s with the skin and metabolic health benefits of omegas 9 and 11.